Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn

Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168

Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.

Merger
Sanofi says US biotech buy ‘fully aligned with our R&D priorities.’ • Source: Shutterstock

Underscoring its determination to build a more focused pipeline, Sanofi is paying nearly $3.7bn in cash for Principia Biopharma, Inc. to acquire the US biotech’s proprietary R&D platform for immune-mediated diseases. The platform has so far produced three promising drug candidates, one of which has already emerged as a key element of the French group’s late-stage pipeline under a previous deal.

Sanofi said on 17 August that under the agreed takeover it would pay $100 per share in cash for Principia,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.